Differentiating HIV-associated nephropathy from antiretroviral drug-induced nephropathy: a clinical challenge

Neelja D. Kumar, Mark A. Perazella

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

With the introduction of potent combination antiretroviral therapy (cART) into clinical practice, HIV-infected patients have garnered much benefit. However, kidney disease continues to be a potential complication in this group. Whereas HIV-associated nephropathy (HIVAN) was the major renal complication prior to cART, co-morbid diseases and adverse renal effects of various drugs, in particular cART, now complicate the landscape. Clinicians now must differentiate HIVAN from cART nephrotoxicity. While sometimes this is easy and relatively straightforward, often the clinician faces a difficult challenge distinguishing these two etiologies of kidney disease. This review will discuss HIVAN and cART-related kidney disease and review the clinical and laboratory data that may be useful in differentiating these processes. Often, however, kidney biopsy may be required to differentiate HIVAN from cART nephrotoxicity as well as other kidney lesions associated with concurrent co-morbidities, both infectious and non-infectious.

Original languageEnglish (US)
Pages (from-to)202-211
Number of pages10
JournalCurrent HIV/AIDS Reports
Volume11
Issue number3
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

AIDS-Associated Nephropathy
Kidney Diseases
Pharmaceutical Preparations
Kidney
Therapeutics
HIV
Morbidity
Biopsy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Differentiating HIV-associated nephropathy from antiretroviral drug-induced nephropathy : a clinical challenge. / Kumar, Neelja D.; Perazella, Mark A.

In: Current HIV/AIDS Reports, Vol. 11, No. 3, 01.09.2014, p. 202-211.

Research output: Contribution to journalReview article

@article{5b76e070d67146c588fb3feb843a64cd,
title = "Differentiating HIV-associated nephropathy from antiretroviral drug-induced nephropathy: a clinical challenge",
abstract = "With the introduction of potent combination antiretroviral therapy (cART) into clinical practice, HIV-infected patients have garnered much benefit. However, kidney disease continues to be a potential complication in this group. Whereas HIV-associated nephropathy (HIVAN) was the major renal complication prior to cART, co-morbid diseases and adverse renal effects of various drugs, in particular cART, now complicate the landscape. Clinicians now must differentiate HIVAN from cART nephrotoxicity. While sometimes this is easy and relatively straightforward, often the clinician faces a difficult challenge distinguishing these two etiologies of kidney disease. This review will discuss HIVAN and cART-related kidney disease and review the clinical and laboratory data that may be useful in differentiating these processes. Often, however, kidney biopsy may be required to differentiate HIVAN from cART nephrotoxicity as well as other kidney lesions associated with concurrent co-morbidities, both infectious and non-infectious.",
author = "Kumar, {Neelja D.} and Perazella, {Mark A.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1007/s11904-014-0209-9",
language = "English (US)",
volume = "11",
pages = "202--211",
journal = "Nature Methods",
issn = "1548-7091",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Differentiating HIV-associated nephropathy from antiretroviral drug-induced nephropathy

T2 - a clinical challenge

AU - Kumar, Neelja D.

AU - Perazella, Mark A.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - With the introduction of potent combination antiretroviral therapy (cART) into clinical practice, HIV-infected patients have garnered much benefit. However, kidney disease continues to be a potential complication in this group. Whereas HIV-associated nephropathy (HIVAN) was the major renal complication prior to cART, co-morbid diseases and adverse renal effects of various drugs, in particular cART, now complicate the landscape. Clinicians now must differentiate HIVAN from cART nephrotoxicity. While sometimes this is easy and relatively straightforward, often the clinician faces a difficult challenge distinguishing these two etiologies of kidney disease. This review will discuss HIVAN and cART-related kidney disease and review the clinical and laboratory data that may be useful in differentiating these processes. Often, however, kidney biopsy may be required to differentiate HIVAN from cART nephrotoxicity as well as other kidney lesions associated with concurrent co-morbidities, both infectious and non-infectious.

AB - With the introduction of potent combination antiretroviral therapy (cART) into clinical practice, HIV-infected patients have garnered much benefit. However, kidney disease continues to be a potential complication in this group. Whereas HIV-associated nephropathy (HIVAN) was the major renal complication prior to cART, co-morbid diseases and adverse renal effects of various drugs, in particular cART, now complicate the landscape. Clinicians now must differentiate HIVAN from cART nephrotoxicity. While sometimes this is easy and relatively straightforward, often the clinician faces a difficult challenge distinguishing these two etiologies of kidney disease. This review will discuss HIVAN and cART-related kidney disease and review the clinical and laboratory data that may be useful in differentiating these processes. Often, however, kidney biopsy may be required to differentiate HIVAN from cART nephrotoxicity as well as other kidney lesions associated with concurrent co-morbidities, both infectious and non-infectious.

UR - http://www.scopus.com/inward/record.url?scp=85027957086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027957086&partnerID=8YFLogxK

U2 - 10.1007/s11904-014-0209-9

DO - 10.1007/s11904-014-0209-9

M3 - Review article

C2 - 24924830

AN - SCOPUS:85027957086

VL - 11

SP - 202

EP - 211

JO - Nature Methods

JF - Nature Methods

SN - 1548-7091

IS - 3

ER -